BRAF and cutaneous squamous cell carcinoma: Cutaneous squamous cell carcinoma (cuSCC) and keratoacanthoma (KA) develop in approximately 20% to 30% of patients who are treated with BRAF (v-raf murine sarcoma viral homolog B1) inhibitors, such as vemurafenib (PLX4032) [1].